Search company, investor...

BMEYE

bmeye.com

Founded Year

2005

Stage

Acquired | Acquired

Total Raised

$12.2M

Valuation

$0000 

About BMEYE

BMEYE is a non-invasive cardiovascular monitoring company. BMEYE has successfully been selling Nexfin, an FDA and CE approved cardiovascular monitor which uses an easy to apply finger sensor to produce accurate beat-to-beat, non-invasive blood pressure and cardiac output data displayed on a touch screen.In October 2012, BMEYE was acquired by Edwards Lifesciences Corporation. The valuation of BMEYE was $42 million. Other terms of the deal were not released.

Headquarters Location

Centerpoint 1, 4th floor Hoogoorddreef 60

1101 BE,

Netherlands

Missing: BMEYE's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BMEYE's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

BMEYE Patents

BMEYE has filed 1 patent.

The 3 most popular patent topics include:

  • Cardiac anatomy
  • Cardiac surgery
  • Cardiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/14/2020

11/22/2022

Cardiac anatomy, Cardiac surgery, Congenital heart defects, Valvular heart disease, Cardiology

Grant

Application Date

8/14/2020

Grant Date

11/22/2022

Title

Related Topics

Cardiac anatomy, Cardiac surgery, Congenital heart defects, Valvular heart disease, Cardiology

Status

Grant

Latest BMEYE News

Earlybird sells BMEYE for €32.5m

Apr 18, 2013

Start a FREE trial or subscribe to continue reading: Start a 1 week free trial Try unquote.com's premium content for a limited period. Register now for your FREE 1 week trial to the ENTIRE site. * not available to previous trialists or subscribers Log In or Subscribe Now If you're already a subscriber, log in using the login tab in the box on your right. Otherwise subscribe now to access the latest private equity news, analysis, views and industry comment on unquote.com for 1 year.

BMEYE Frequently Asked Questions (FAQ)

  • When was BMEYE founded?

    BMEYE was founded in 2005.

  • What is BMEYE's latest funding round?

    BMEYE's latest funding round is Acquired.

  • How much did BMEYE raise?

    BMEYE raised a total of $12.2M.

  • Who are the investors of BMEYE?

    Investors of BMEYE include Edwards Lifesciences, EQT Life Sciences, TIIN Capital, 360 Capital Partners, Earlybird Venture Capital and 3 more.

  • Who are BMEYE's competitors?

    Competitors of BMEYE include Sotera Wireless, Cheetah Medical, RF Surgical Systems, eCardio Diagnostics, Sensible Medical Innovations and 11 more.

Compare BMEYE to Competitors

A
ArKal Medical

Arkal Medical is developing a continuous blood glucose sensor for diabetes.

N
Novoculi

Located in Hanover, NH and San Francisco, CA, Novoculi is a medical device company focused on developing a non-invasive, optical blood glucose monitor. Novoculi's Noninvasive Blood Glucose Monitor aims to build on physiologically demonstrated optical phenomena which forms the basis for Novoculi's technology. Novoculi hopes to leverage its technology to develop a non-invasive blood glucose monitor which will allow its patient population to better manage their blood glucose without a painful finger stick.

A
Advanced BioSensors

Advanced BioSensors is developing a miniaturized blood glucose sensor for use in the treatment of diabetes.

L
Luminous Medical

Luminous Medical is developing a new device to allow the near continuous measurement of blood glucose and other analytes in the hospital environment.

C
Cardiophotonics

Cardiophotonics develops non invasive blood monitors used to detect cardiac arrhythmia and dehydration

S
Sotera Wireless

Sotera Wireless is committed to the development, marketing and sale of a new generation early detection surveillance monitoring system. Its flagship product, the ViSi Mobile, is designed to improve patient safety by detecting early signs of deterioration in virtually any care setting, enabling early intervention and rapid response without limiting the patient's freedom of movement

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.